2021 Clinical Trials Sleep THC 
Cannabis Law Report
JUNE 7, 2021
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
The Cannigma
APRIL 12, 2023
CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. Like THC , CBN is a natural anti-inflammatory. Here’s what they found.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
MARCH 7, 2022
So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. Long before THC was discovered in the 1940s , CBN was first identified at the turn of the 20th century from a plant that was then known as Indian hemp. Converting THC to CBN happens through oxidation.
Cannabis Law Report
OCTOBER 29, 2021
(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The Company is preparing an INDA submission to the FDA for a Phase 2/3 trial for the use of IGC-AD1 to address symptoms associated with Alzheimer’s disease.
Cannabis Law Report
JULY 8, 2021
The Company expects to finalize the agreement with the research institute and commence studies by Fall 2021. cbdMD began its first phase of research in the Fall of 2020, with its first in vivo animal study and clinical trials. produced, THC-free 1 CBD products. About cbdMD, Inc. cbdMD, Inc. and are difficult to predict.
Cannabis Law Report
AUGUST 2, 2021
During the four-week study, participants will use the Radicle Science platform to track consumption and effectiveness of orally ingested CBD products on well-being, quality of life, pain, sleep disturbance, and anxiety. CBD is much more subtle in its effects and quite benign compared to THC.
Cannabis Law Report
AUGUST 19, 2021
Such products will generate sales of £690 million ($856 million, 811 million euros) in 2021, according to the Association for the Cannabinoid Industry (ACI). Such products are stripped of psychoactive tetrahydrocannabinol or THC molecules, which are found in recreational cannabis that remains illegal in Britain.
Expert insights. Personalized for you.
105 
Let's personalize your content